Pharmacokinetics of a single, large dose of cholecalciferol

Ilahi, M.A.; Armas, Laura A.G.; Heaney, Robert P.

doi:10.1093/ajcn/87.3.688

Cited by 182 publications

(148 citation statements)

References 13 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, with HyD at a dose of 20 mg, the 25(OH)D threshold of 30 ng/mL was achieved in all women already at 35 days of treatment, and after 3 to 4 months, the 25(OH)D level rose to a mean concentration maximum of 69.5 ng/mL. As demonstrated by Ilahi and colleagues, (27) 3 ; however, only with a much higher oral bolus of 2500 mg (100,000 IU).…”

Section: Discussionmentioning

confidence: 73%

Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity

Bischoff‐Ferrari

Dawson‐Hughes

Stöcklin³

et al. 2011

Journal of Bone and Mineral Research

168

176

View full text Add to dashboard Cite

To test the effect of 25(OH)D 3 (HyD) compared to vitamin D 3 on serum 25-hydroxyvitamin D levels (25(OH)D), lower extremity function, blood pressure, and markers of innate immunity. Twenty healthy postmenopausal women with an average 25(OH)D level of 13.2 AE 3.9 ng/mL (mean AE SD) and a mean age of 61.5 AE 7.2 years were randomized to either 20 mg of HyD or 20 mg (800 IU) of vitamin D 3 per day in a double-blind manner. We measured on 14 visits over 4 months, 25(OH)D serum levels, blood pressure, and seven markers of innate immunity (eotaxin, interleukin [IL]-8, IL-12, interferon gamma-induced protein 10 kDa , monocyte chemotactic protein-1 [MCP-1], macrophage inflammatory protein beta , and ''Regulated upon Activation, Normal T-cell Expressed, and Secreted'' [RANTES]). At baseline and at 4 months, a test battery for lower extremity function (knee extensor and flexor strength, timed up and go, repeated sit-to-stand) was assessed. All analyses were adjusted for baseline measurement, age, and body mass index. Mean 25(OH)D levels increased to 69.5 ng/mL in the HyD group. This rise was immediate and sustained. Mean 25(OH)D levels increased to 31.0 ng/mL with a slow increase in the vitamin D 3 group. Women on HyD compared with vitamin D 3 had a 2.8-fold increased odds of maintained or improved lower extremity function (odds ratio [OR] ¼ 2.79; 95% confidence interval [CI], 1.18-6.58), and a 5.7-mmHg decrease in systolic blood pressure ( p ¼ 0.0002). Both types of vitamin D contributed to a decrease in five out of seven markers of innate immunity, significantly more pronounced with HyD for eotaxin, IL-12, MCP-1, and MIP-1 b. There were no cases of hypercalcemia at any time point. Twenty micrograms (20 mg) of HyD per day resulted in a safe, immediate, and sustained increase in 25(OH)D serum levels in all participants, which may explain its significant benefit on lower extremity function, systolic blood pressure, and innate immune response compared with vitamin D 3 . ß

show abstract

Section: Discussionmentioning

confidence: 73%

Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity

Bischoff‐Ferrari

Dawson‐Hughes

Stöcklin³

et al. 2011

Journal of Bone and Mineral Research

168

176

View full text Add to dashboard Cite

show abstract

“…The authors did not provide information as to how many participants achieved a value of 480 nmol/l. Vitamin D3 in a single oral dose of 100 000 U given to adult men and women was safe and effective in raising 25OHD to 480 nmol/l in 93% of the participants (Ilahi et al, 2008). Mean 25OHD stayed above 80 nmol/l for up to 70 days and approximately above 70 nmol/l for 90 days.…”

Section: Discussionmentioning

confidence: 91%

Vitamin D replacement in pregnant women in rural north India: a pilot study

et al. 2009

View full text Add to dashboard Cite

Hypovitaminosis D is common in both urban and rural Indians. The dose of vitamin D needed for the treatment of its deficiency during pregnancy is not clear. We conducted a study in rural Indians to evaluate the effect of cholecalciferol supplementation during routine antenatal visits on maternal 25 hydroxyvitamin D (25OHD) at delivery. Pregnant women received either no cholecalciferol (Group A) or 60 000 U (Group B) in the fifth month of gestation or 120 000 U each in the fifth and seventh gestational months (Group C). Serum 25OHD was measured at baseline (n ¼ 139) and at delivery (n ¼ 84). Median (interquartile range) 25OHD

show abstract

“…It should first be noted that vitamin D supplementation was delivered once a month in our study and that DSLs once vitamin D supplementation had been started were measured a few days before a monthly intake. However, we know from pharmacokinetic studies that after a single dose of 100,000 IU of cholecalciferol [Ilahi et al 2008] (i.e. the same dose as in our study), the DSL decreases only slightly for the second half of the month following the intake, and that, with regular monthly intakes of vitamin D when compared with analogous weekly or daily intakes [Ish-Shalom et al 2009 , (2) in compliance with vitamin D intake or even (3) in changes in the lifestyle habits of some patients, once they were aware of a potential role of the environment in the course of their disease.…”

Section: Relationship Between the Relapse Rate And Vitamin D Statusmentioning

confidence: 99%

Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation

Pierrot‐Deseilligny

Rivaud-Péchoux

Clerson

et al. 2012

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Abstract:Background: Vitamin D could play a protective role in multiple sclerosis. Methods:In an observational, uncontrolled study, vitamin D3 supplementation (3010 IU/day on average) was given to 156 consecutive patients with relapsing-remitting multiple sclerosis, under first-line immunomodulatory therapy and with initial 25-OH-D serum level lower than 100 nmol/l (40 ng/ml). Relapses were determined for 29.1 ± 8.4 months during vitamin D and 29.8 ± 10.1 months before supplementation. The 25-OH-D level was measured before supplementation and several times during supplementation. The incidence rate of relapses before and during supplementation was estimated using negative binomial regression models with follow-up durations as offset terms. The incidence rate and incidence rate ratio of relapses at various 25-OH-D levels were also calculated using negative binomial regression models. Results: In 76 patients, immunomodulatory therapy preceded vitamin D supplementation (by 4.2 ± 2.7 years) and in 80 patients both treatments were started simultaneously. Under supplementation, the 25-OH-D level increased from 49 ± 22 nmol/l to 110 ± 26 nmol/l on average. Pooling data collected before and during supplementation, we found a significant strong inverse relationship between the relapse incidence rate and the 25-OH-D level (p < 0.0001), suggesting that vitamin D did indeed influence the relapse rate. Results of univariate, bivariate and multivariate analyses were analogous: in the multivariate model adjusted for age, disease duration and previous use of immunomodulatory therapy, every 10 nmol increase in 25-OH-D level was associated with a reduction in the relapse incidence rate of 13.7%. Dividing iteratively the population made up of pooled periods into two subgroups according to the 25-OH-D levels, the relapse incidence rate ratio decreased as the 25-OH-D level increased up to 110 nmol/l, but a plateau effect was observed beyond this limit. Conclusion: Further studies are warranted for accurate quantification of the vitamin D effect.

show abstract

Pharmacokinetics of a single, large dose of cholecalciferol

Abstract: Cholecalciferol (100,000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be < or =2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials.gov as #NCT00473239.

Cited by 182 publications

References 13 publications

Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity

Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity

Vitamin D replacement in pregnant women in rural north India: a pilot study

Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation

Contact Info

Product

Resources

About